Biopsy versus partial versus gross total resection in older patients with high-grade glioma: A systematic review and meta-analysis

Neuro-Oncology

Volumn 17, Issue 6, 2015, Pages 868-881

  Almenawer, Saleh A ^a   Badhiwala, Jetan H ^b   Alhazzani, Waleed ^a   Greenspoon, Jeffrey ^a   Farrokhyar, Forough ^a   Yarascavitch, Blake ^d   Algird, Almunder ^a   Kachur, Edward ^a   Cenic, Aleksa ^a   Sharieff, Waseem ^c   Klurfan, Paula ^a   Gunnarsson, Thorsteinn ^a   Ajani, Olufemi ^a   Reddy, Kesava ^a   Singh, Sheila K ^a   Murty, Naresh K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Elderly; Extent of resection; Malignant glioma; Meta analysis; Systematic review

Indexed keywords

ADULT; AGED; BRAIN SURGERY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONVALESCENCE; CRANIOTOMY; ELDERLY CARE; GLIOBLASTOMA; GLIOMA; HUMAN; INTERMETHOD COMPARISON; KARNOFSKY PERFORMANCE STATUS; META ANALYSIS; MIDDLE AGED; MORBIDITY; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT SAFETY; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; REVIEW; RISK ASSESSMENT; SURGICAL TECHNIQUE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR BIOPSY; BIOPSY; BRAIN NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; MALE; MORTALITY; NEUROSURGERY; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOPSY; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 84937839886     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou349     Document Type: Review

References (81)

1. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(Suppl 5):v1-v49.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
3. Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002;4(4):278-299.
4. Nayak L, Iwamoto FM. Primary brain tumors in the elderly. Curr Neurol Neurosci Rep. 2010;10(4):252-258.
5. Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000. Cancer. 2004;101(10):2293-2299.
6. Desmeules M, Mikkelsen T, Mao Y. Increasing incidence of primary malignant brain tumors: influence of diagnostic methods. J Natl Cancer Inst. 1992;84(6):442-445.
7. Davis DL, Hoel D, Fox J, et al. International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA. Lancet. 1990;336(8713):474-481.
8. Barnholtz-Sloan JS, Williams VL, Maldonado JL, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg. 2008;108(4):642-648.
9. Iwamoto FM, Reiner AS, Panageas KS, et al. Patterns of care in elderly glioblastoma patients. Ann Neurol. 2008;64(6):628-634.
10. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
11. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707-715.
12. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916-926.
13. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008;7(12):1152-1160.
14. Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12(11):997-1003.
15. Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol. 2013;14(9):e370-e379.
16. Kita D, Ciernik IF, Vaccarella S, et al. Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology. 2009;33(1):17-22.
17. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2014;310(17):1842-1850.
18. Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis. J Neurosurg. 2010;112(5):1020-1032.
19. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62(4):753-764; discussion 264-266.
20. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
21. Moher D, Liberati A, Tetzlaff J, et al.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269.
22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). 2011. http://handbook.cochrane.org/.
23. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In:Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949:199-205.
24. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-193.
25. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
26. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
27. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
28. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2011. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed April 1, 2013.
29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
30. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
31. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-1101.
32. Whittle IR, Denholm SW, Gregor A. Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. Surg Neurol. 1991;36(2):106-111.
33. Ampil F, Fowler M, Kim K. Intracranial astrocytoma in elderly patients. J Neurooncol. 1992;12(2):125-130.
34. Kelly PJ, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery. 1994;34(1):62-66; discussion 6-7.
35. Mohan DS, Suh JH, Phan JL, et al. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys. 1998;42(5):981-987.
36. Jeremic B, Shibamoto Y, Grujicic D, et al. Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study. J Neurooncol. 1999;44(1):85-90.
37. Pierga JY, Hoang-Xuan K, Feuvret L, et al. Treatment of malignant gliomas in the elderly. J Neurooncol. 1999;43(2):187-193.
38. Whittle IR, Basu N, Grant R, et al. Management of patients aged >60 years with malignant glioma: good clinical status and radiotherapy determine outcome. Br J Neurosurg. 2002;16(4):343-347.
39. Muacevic A, Kreth FW. Quality-adjusted survival after tumor resection and/or radiation therapy for elderly patients with glioblastoma multiforme. J Neurol. 2003;250(5):561-568.
40. Patwardhan RV, Shorter C, Willis BK, et al. Survival trends in elderly patients with glioblastoma multiforme: resective surgery, radiation, and chemotherapy. Surg Neurol. 2004;62(3):207-213; discussion 14-15.
41. Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien). 2003;145(1):5-10.
42. Chinot OL, Barrie M, Frauger E, et al. Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer. 2004;100(10):2208-2214.
43. Kleinschmidt-DeMasters BK, Lillehei KO, Varella-Garcia M. Glioblastomas in the older old. Arch Pathol Lab Med. 2005;129(5):624-631.
44. Combs SE, Wagner J, Bischof M, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys. 2008;70(4):987-992.
45. Sijben AE, McIntyre JB, Roldan GB, et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol. 2008;89(1):97-103.
46. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564-576; discussion 76.
47. Gerstein J, Franz K, Steinbach JP, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol. 2010;97(3):382-386.
48. Kimple RJ, Grabowski S, Papez M, et al. Concurrent temozolomide and radiation, a reasonable option for elderly patients with glioblastoma multiforme? Am J Clin Oncol. 2010;33(3):265-270.
49. Lai R, Hershman DL, Doan T, et al. The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme. Neuro Oncol. 2010;12(2):190-198.
50. Laigle-Donadey F, Figarella-Branger D, Chinot O, et al. Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol. 2010;99(1):89-94.
51. Chaichana KL, Garzon-Muvdi T, Parker S, et al. Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol. 2011;18(1):239-245.
52. Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neurooncol. 2011;103(3):611-618.
53. Kushnir I, Tzuk-Shina T. Efficacy of treatment for glioblastoma multiforme in elderly patients (65+): a retrospective analysis. Isr Med Assoc J. 2011;13(5):290-294.
54. Hashem SA, Salem A, Al-Rashdan A, et al. Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme. J Med Imaging Radiat Oncol. 2012;56(2):204-210.
55. Oszvald A, Guresir E, Setzer M, et al. Glioblastoma therapy in the elderly and the importance of the extent of resection regardless of age. J Neurosurg. 2012;116(2):357-364.
56. Scott JG, Bauchet L, Fraum TJ, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012;118(22):5595-5600.
57. Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients. J Neurosurg. 2013;118(4):786-798.
58. Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. J Neurooncol. 2012;110(2):227-235.
59. Fariselli L, Pinzi V, Milanesi I, et al. Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre. Strahlenther Onkol. 2013;189(6):456-461.
60. Lee JH, Jung TY, Jung S, et al. Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. J Clin Neurosci. 2013;20(4):503-508.
61. Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas. J Clin Neurosci. 2013;21(5):773-778.
62. Noorbakhsh A, Tang JA, Marcus LP, et al. Gross-total resection outcomes in an elderly population with glioblastoma: a SEER-based analysis. J Neurosurg. 2014;120(1):31-39.
63. Pichler J, Hoellmüller I, Ghanim B, et al. Treatment in elderly glioblastoma patients: general reduction of standard therapy should be avoided. prognostic value of MGMT is questionable. J Cancer Ther. 2013;4:1217-1223.
64. Uzuka T, Asano K, Sasajima T, et al. Treatment outcomes in glioblastoma patients aged 76 years or older: a multicenter retrospective cohort study. J Neurooncol. 2014;116(2):299-306.
65. Paszat L, Laperriere N, Groome P, et al. A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51(1):100-107.
66. Harbaugh KS, Black PM. Strategies in the surgical management of malignant gliomas. Semin Surg Oncol. 1998;14(1):26-33.
67. Lee Y, Scheck AC, Cloughesy TF, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008;1:52.
68. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707-718.
69. Kloosterhof NK, Bralten LB, Dubbink HJ, et al. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol. 2011;12(1):83-91.
70. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
71. Bozdag S, Li A, Riddick G, et al. Age-specific signatures of glioblastoma at the genomic, genetic, and epigenetic levels. PloS One. 2013;8(4):e62982.
72. Kaur B, Tan C, Brat DJ, et al. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol. 2004;70(2):229-243.
73. Chi AS, Sorensen AG, Jain RK, et al. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009;14(6):621-636.
74. Evers BM, Townsend CM Jr., Thompson JC. Organ physiology of aging. Surg Clin North Am. 1994;74(1):23-39.
75. Turrentine FE, Wang H, Simpson VB, et al. Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg. 2006;203(6):865-877.
76. Page MJ, Poritz LS, Kunselman SJ, et al. Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg. 2002;6(4):606-613.
77. Vemuri C, Wainess RM, Dimick JB, et al. Effect of increasing patient age on complication rates following intact abdominal aortic aneurysm repair in the United States. J Surg Res. 2004;118(1):26-31.
78. Bernstein M. Brain tumour surgery in the elderly: a brief reappraisal. Can J Surg. 1996;39(2):147-150.
79. Tomita T, Raimondi AJ. Brain tumors in the elderly. JAMA. 1981;246(1):53-55.
80. Cabantog AM, Bernstein M. Complications of first craniotomy for intra-axial brain tumour. Can J Neurol Sci. 1994;21(3):213-218.
81. Bernstein M, Parrent AG. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. J Neurosurg. 1994;81(2):165-168.